Earnings Update: Vijaya Diagnostic Centre Limited (NSE:VIJAYA) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

It's been a sad week for Vijaya Diagnostic Centre Limited (NSE:VIJAYA), who've watched their investment drop 19% to ₹922 in the week since the company reported its quarterly result. Results look mixed - while revenue fell marginally short of analyst estimates at ₹1.7b, statutory earnings were in line with expectations, at ₹11.59 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

View our latest analysis for Vijaya Diagnostic Centre

Following the latest results, Vijaya Diagnostic Centre's seven analysts are now forecasting revenues of ₹8.32b in 2026. This would be a substantial 25% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to jump 41% to ₹19.43. In the lead-up to this report, the analysts had been modelling revenues of ₹8.41b and earnings per share (EPS) of ₹19.57 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

The analysts reconfirmed their price target of ₹1,130, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Vijaya Diagnostic Centre at ₹1,265 per share, while the most bearish prices it at ₹930. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Vijaya Diagnostic Centre's past performance and to peers in the same industry. The analysts are definitely expecting Vijaya Diagnostic Centre's growth to accelerate, with the forecast 20% annualised growth to the end of 2026 ranking favourably alongside historical growth of 12% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 19% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Vijaya Diagnostic Centre is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Vijaya Diagnostic Centre going out to 2027, and you can see them free on our platform here.

It might also be worth considering whether Vijaya Diagnostic Centre's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.